Skip to main page content
U.S. flag

An official website of the United States government

Dot gov

The .gov means it’s official.
Federal government websites often end in .gov or .mil. Before sharing sensitive information, make sure you’re on a federal government site.

Https

The site is secure.
The https:// ensures that you are connecting to the official website and that any information you provide is encrypted and transmitted securely.

Access keys NCBI Homepage MyNCBI Homepage Main Content Main Navigation

Search Page

Filters

My Custom Filters

Publication date

Text availability

Article attribute

Article type

Additional filters

Article Language

Species

Sex

Age

Other

Search Results

3,249 results

Filters applied: . Clear all
Results are displayed in a computed author sort order. The Publication Date timeline is not available.
Page 1
Discovery of 5,7-Dihydro-6H-pyrrolo[2,3-d]pyrimidin-6-ones as Highly Selective CDK2 Inhibitors.
Sokolsky A, Winterton S, Kennedy K, Drake K, Stump K, Huo L, Lo Y, Ye M, Covington M, Diamond S, Yang YO, Kim S, Yeleswaram S, Wu L, Yao W. Sokolsky A, et al. Among authors: lo y. ACS Med Chem Lett. 2022 Oct 6;13(11):1797-1804. doi: 10.1021/acsmedchemlett.2c00408. eCollection 2022 Nov 10. ACS Med Chem Lett. 2022. PMID: 36385925 Free PMC article.
A Potent and Selective Dual Inhibitor of AXL and MERTK Possesses Both Immunomodulatory and Tumor-Targeted Activity.
Rios-Doria J, Favata M, Lasky K, Feldman P, Lo Y, Yang G, Stevens C, Wen X, Sehra S, Katiyar K, Liu K, Wynn R, Harris JJ, Ye M, Spitz S, Wang X, He C, Li YL, Yao W, Covington M, Scherle P, Koblish H. Rios-Doria J, et al. Among authors: lo y. Front Oncol. 2020 Dec 7;10:598477. doi: 10.3389/fonc.2020.598477. eCollection 2020. Front Oncol. 2020. PMID: 33425754 Free PMC article.
The effect of CYP3A4 inhibition or induction on the pharmacokinetics and pharmacodynamics of orally administered ruxolitinib (INCB018424 phosphate) in healthy volunteers.
Shi JG, Chen X, Emm T, Scherle PA, McGee RF, Lo Y, Landman RR, McKeever EG Jr, Punwani NG, Williams WV, Yeleswaram S. Shi JG, et al. Among authors: lo y. J Clin Pharmacol. 2012 Jun;52(6):809-18. doi: 10.1177/0091270011405663. Epub 2011 May 20. J Clin Pharmacol. 2012. PMID: 21602517 Clinical Trial.
Pharmacological characterization of INCB3344, a small molecule antagonist of human CCR2.
Shin N, Baribaud F, Wang K, Yang G, Wynn R, Covington MB, Feldman P, Gallagher KB, Leffet LM, Lo YY, Wang A, Xue CB, Newton RC, Scherle PA. Shin N, et al. Among authors: lo yy. Biochem Biophys Res Commun. 2009 Sep 18;387(2):251-5. doi: 10.1016/j.bbrc.2009.06.135. Epub 2009 Jul 1. Biochem Biophys Res Commun. 2009. PMID: 19576173
Downmodulation of key inflammatory cell markers with a topical Janus kinase 1/2 inhibitor.
Punwani N, Burn T, Scherle P, Flores R, Shi J, Collier P, Hertel D, Haley P, Lo Y, Waeltz P, Rodgers J, Shepard S, Vaddi K, Yeleswaram S, Levy R, Williams W, Gottlieb AB. Punwani N, et al. Among authors: lo y. Br J Dermatol. 2015 Oct;173(4):989-97. doi: 10.1111/bjd.13994. Epub 2015 Oct 14. Br J Dermatol. 2015. PMID: 26123031 Clinical Trial.
3,249 results